Dendrite Clinical Systems is delighted to report that our Managing Director, Dr Peter Walton, has published a chapter discussing the value of clinical registries in new publication on Laparoscopic Sleeve Gastrectomy (LSG). In his Chapter, Dr Peter Walton outlines value of national bariatric registries and their capability to deliver evidence on a global basis, as well as providing some practical perspectives on best practice when setting out to start a national registry and how to keep a good registry going.
Dendrite Clinical Systems and the Institute for Health Research (IGES) in Berlin, Germany, have initiated the Outpatient Treatment of COVID-19 Infections (ABC-19) study, to record data on the treatment of COVID-19 patients and discover more about the outpatient course of the disease, the individual risk factors of patients that contribute to severe COVID-19 courses and the procedures of general practitioners (GPs).
Researchers at the University College London and University College London Hospitals NHS Foundation Trust), London, UK, have reported that the vast majority of participants with new onset loss of smell were positive for COVID19, and this acute loss of sense of smell needs to be considered globally as a criterion for self-isolation, testing and contact tracing in order to contain the spread of COVID-19.
Dendrite Clinical Systems’ innovative “Intellect Web” software has been chosen by an international group of 17 leading diabetes experts from the multidisciplinary Diabetes Surgery Summit (DSS), as the platform on which the CoviDiab project will establish a Global Registry to collect new cases of diabetes in patients with COVID-19.
UK-ROPE outcomes demonstrate value of registries
The positive outcomes from the UK-ROPE (Registry of prostate embolization) – a collaboration initiated by British Society of Interventional Radiology (BSIR) and Dendrite Clinical Systems – has resulted in a National Institute of Health and Care Excellence (NICE) recommendation that prostate artery embolization (PAE) should be made available by the NHS. The registry was jointly funded by the National Institute of Health and Care Excellence (NICE), the British Society of Interventional Radiology (BSIR), the British Association of Urological Surgeons (BAUS) and Cook Medical.
UK-ROPE utilised Dendrite’s unique ‘Intellect Web’ national registry software to facilitate on-line data entry. The Registry was accessed using a range of modern html-5 compatible web browsers, allowing registrants to enter data securely without the need to install additional software or perform any complex system configurations.
“I would like to congratulate the investigators of ROPE on the outcomes of the registry,” said Dr Peter Walton, Managing Director of Dendrite Clinical Systems. “The outcomes from ROPE and recommendation by NICE again demonstrates the power of ‘real world’ data from clinical registries.”
Prostate artery embolization or benign prostatic hyperplasia (BPH) is used to treat non-cancerous enlargement of the prostate, a very common condition in older men, and blocks some of the blood supply to the prostate using tiny synthetic beads, causing the troublesome tissue to shrink and die, and importantly, spares patients from undergoing surgery and potential side-effects such as impotence.
When compared directly with a matched cohort of men undergoing transurethral resection of the prostate (TURP), patients who underwent embolization had less hospital stay, fewer erectile function problems, improved urinary flow and an average reduction of prostate size of nearly 30%.
"It (PAE) is a particularly good option for men who are not yet ready to undergo more invasive prostate surgery. Maintaining sexual function and fertility is one of its main strengths,” Dr Nigel Hacking, Chairman & clinical lead for the UK-ROPE Standing Committee and consultant interventional radiologist at University Hospital Southampton, told the BBC. "I hope with NICE's recommendations, that more centres will be able to introduce PAE services in the not too distant future."
Since 1993, Dendrite Clinical Systems has been developing specialist clinical databases, analysis software, consultancy and publishing services that empower the international healthcare sector with the data they need. The company now has two offices in the UK and agents across four continents, and has expanded its global user base across hundreds of hospitals, with over 170 national and international registries in more than 40 countries.
